Results 51 to 60 of about 9,511 (212)

Clinical Validation of Plasma p‐217tau in Neurological Diseases

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Plasma p‐217tau is a minimally invasive but specific biomarker for diagnosing Alzheimer's disease (AD). However, its disease specificity remains to be clinically evaluated. We validated the reliability of the p‐217tau biomarker in 12 other neurological diseases.
Takeshi Kawarabayashi, Takumi Nakamura, Ryoma Takahashi, Tetsuya Ueda, Seiji Kinoshita, Chikage Uchida, Takashi Sugawara, Kentaro Hashimoto, Kunihiko Ishizawa, Masakuni Amari, Hiroo Kasahara, Yoshio Ikeda, Masamitsu Takatama, Mikio Shoji   +13 more
wiley   +1 more source

Concentrations of B cell-activating factor, aquaporin-4 antibody and brain-derived neurotrophic factor in neuromyelitis optica spectrum disorder

Türk Biyokimya Dergisi, 2022
To explore the correlations of B cell-activating factor (BAFF), aquaporin-4 antibody (AQP4-Ab) and brain-derived neurotrophic factor (BDNF) with the severity of neuromyelitis optica spectrum disorder (NMOSD).
Li Suping, Fu Jing, Xu Fei, Yu Liang, Yu Qian, Yu Nengwei   +5 more
doaj   +1 more source

Neuromyelitis optica spectrum disorder as a paraneoplastic manifestation of lung adenocarcinoma expressing aquaporin-4. [PDF]

, 2015
Neuromyelitis optica spectrum disorder as a paraneoplastic manifestation of lung adenocarcinoma expressing aquaporin ...
Rindi, Guido, Di Iorio, Riccardo, Erra, Carmen, Sabatelli, Mario, Damato, Valentina, Ferilli, Michela, Ferilli, Michela Ada Noris, Iorio, Raffaele   +7 more
core   +1 more source

Understanding Further the Phenotypic Spectrum of Central Nervous System Inflammatory Demyelinating Disorders Using Unsupervised Clustering

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Central nervous system (CNS) inflammatory demyelinating syndromes, including multiple sclerosis (MS), aquaporin‐4 antibody–positive neuromyelitis optica spectrum disorder (AQP4 + NMOSD), and myelin oligodendrocyte glycoprotein (MOG) antibody–associated disease (MOGAD), occasionally overlap.
Bade Gulec, Elif Everest, Melih Tutuncu, Ugur Bilge, Sabahattin Saip, Ugur Uygunoglu, Aksel Siva   +6 more
wiley   +1 more source

N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes [PDF]

, 2010
Antibodies to the N-methyl-d-aspartate subtype of glutamate receptor have been associated with a newly-described encephalopathy that has been mainly identified in young females with ovarian tumours.
Irani, Sarosh R., Zandi, Michael S, Friese, MA, Kullmann, DM, Zuliani, Luigi, Bien, Christian G., Waters, Patrick, Irani, SR, Friese, Manuel A, Galea, Ian, Kullmann, Dimitri M., Maxwell, S, Lang, Bethan, Lang, B, Zuliani, L, Bien, CG, Bera, K, Maxwell, Susan, Zandi, MS, Vincent, Angela, Beeson, David, Vincent, A, Friese, Manuel A., Galea, I, Bera, Katarzyna, Zandi, Michael S., Waters, P, Beeson, D   +27 more
core   +2 more sources

Neuromyelitis optica spectrum disorder (NMOSD) – diagnosis, epidemiology, clinical course, treatment

Aktualności Neurologiczne, 2019
Devic’s disease (neuromyelitis optica, NMO) was first described under this name in 1894, and it was originally thought of as a variant of multiple sclerosis.
Agnieszka Damiza-Detmer, Marta Milewska-Jędrzejczak, Małgorzata Pawełczyk, Izabela Damiza, Andrzej Głąbiński   +4 more
doaj   +1 more source

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan, Lei Zhou, Jingzi ZhangBao, Hongmei Tan, Zhouzhou Wang, Chao Quan   +5 more
wiley   +1 more source

MRI Patterns Distinguish Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis [PDF]

, 2021
Objective: To develop an MRI based diagnostic algorithm to distinguish AQP4 positive neuromyelitis optica spectrum disorder (NMOSD) from multiple sclerosis (MS).
Broadley, Simon, Arnett, Simon, Bhuta, Sandeep, Bukhari, Wajih, Khalilidehkordi, Elham, Prain, Kerri, Woodhall, Mark, Bundell, Christine, Abernethy, David, Blum, Stefan, Clarke, Laura, Silvestrini, Roger, Sanchez, Sofia Jimenez, O'Gorman, Cullen, Heshmat, Sam, et al.   +15 more
core  

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin, Binbin Xue, Dewei Xie, Jia Li, Juyuan Pan, Lanbing Zhu, Qiaowen Tong, Jing Lin, Ruofan Zhu, Xu Zhang, Junhui Xia, Xiang Li   +11 more
wiley   +1 more source

MOGAD Is the Most Common Cause of Isolated Optic Neuritis in Children

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives The study aimed to characterize the clinical features, etiologies, and outcomes of isolated, first‐time pediatric ON in the post‐MOG‐IgG era. Methods This was a single‐center retrospective cohort study at Texas Children's Hospital of patients diagnosed with first‐time ON between 2018–2024, with follow‐up data collected through 2025.
Chaitanya Aduru, Akansha Chandrasekar, Kyla Blasingame, Jonathan Rosen, Jesse M. Levine, Karla Salazar, Madhuri Chilakapati, Rod Foroozan, Victoria Hardwick, Jonathan M. Yarimi, Nikita Shukla, Timothy E. Lotze, Kristen S. Fisher, Alexander J. Sandweiss   +13 more
wiley   +1 more source